Cite
HARVARD Citation
Coates, L. et al. (n.d.). AB0772 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved low disease activity related to psoriatic arthritis disease activity score (PASDAS). Annals of the rheumatic diseases. p. 1326. [Online].